MEIRAGTX HOLDINGS PLC

(MGTX)
  Report
Real-time Estimate Cboe BZX  -  03:37 2022-07-06 pm EDT
8.195 USD   +4.80%
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients
MT
06/28TRANSCRIPT : MeiraGTx Holdings plc - Special Call
CI
06/28MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
7.75(c) 7.57(c) 7.57(c) 7.82(c) 8.17 Last
187 943 169 000 144 279 128 025 91 347 Volume
+4.59% -2.32% 0.00% +3.30% +4.48% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 34,4 M - -
Net income 2022 -103 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,34x
Yield 2022 -
Sales 2023 45,9 M - -
Net income 2023 -106 M - -
Net Debt 2023 - - -
P/E ratio 2023 -3,80x
Yield 2023 -
Capitalization 350 M 350 M -
Capi. / Sales 2022 10,2x
Capi. / Sales 2023 7,61x
Nbr of Employees 315
Free-Float 72,0%
More Financials
Company
MeiraGTx Holdings plc is an integrated clinical stage gene therapy company. The Company is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1,... 
More about the company
Ratings of MeiraGTx Holdings plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MEIRAGTX HOLDINGS PLC
06/28MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/28TRANSCRIPT : MeiraGTx Holdings plc - Special Call
CI
06/28MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demo..
GL
06/28MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demo..
AQ
06/28MeiraGTx Holdings plc Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinic..
CI
06/27MEIRAGTX HOLDINGS PLC : Change in Directors or Principal Officers (form 8-K)
AQ
06/27Meiragtx Holdings plc Announces Resignation of Joel S. Marcus from Board of Directors
CI
06/09MEIRAGTX HOLDINGS PLC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/13Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
MT
05/13Barclays Lowers MeiraGTx Holdings's Price Target to $18 From $32, Maintains Overweight ..
MT
05/13Piper Sandler Adjusts MeiraGTx Holdings' Price Target to $30 From $40, Reiterates Overw..
MT
05/12MEIRAGTX HOLDINGS PLC Management's Discussion and Analysis of Financial Condition and ..
AQ
05/12MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/12MeiraGTx Reports First Quarter 2022 Financial and Operational Results
GL
05/10TRANSCRIPT : MeiraGTx Holdings plc Presents at Bank of America 2022 Healthcare Conference,..
CI
More news
News in other languages on MEIRAGTX HOLDINGS PLC
06/28MeiraGTx Holdings plc annonce des données de premier plan positives provenant de l'étud..
06/27Meiragtx Holdings plc annonce la démission de Joel S. Marcus du conseil d'administratio..
05/12MeiraGTx Holdings plc annonce ses résultats pour le premier trimestre se terminant le 3..
05/04MeiraGTx Holdings plc présente des données cliniques sur le Botaretigene Sparoparvovec ..
04/27MeiraGTx nomme Debra Yu au conseil d'administration
More news
Analyst Recommendations on MEIRAGTX HOLDINGS PLC
More recommendations
Chart MEIRAGTX HOLDINGS PLC
Duration : Period :
MeiraGTx Holdings plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEIRAGTX HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 7,82 $
Average target price 31,00 $
Spread / Average Target 296%
EPS Revisions
Managers and Directors
Alexandria Forbes President, Chief Executive Officer & Director
Richard Giroux Chief Operating & Financial Officer
Keith Reginald Harris Director
Robert K. Zeldin Chief Medical Officer
Ellen Hukkelhoven Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEIRAGTX HOLDINGS PLC-67.06%350
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.30%49 127
BIONTECH SE-37.54%39 133